Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuel Messas

Showing results (1-10 of 134) with videos related to

Pageof 14
Sort By:
Archives of Cardiovascular Diseases|June 2, 2024
Non-invasive ultrasound therapy for aortic valve stenosis: State of the artEmmanuel Messas
Archives of Cardiovascular Diseases|May 28, 2013
Ischemic mitral regurgitation: new conceptsCatherine Szymanski, Emmanuel Messas
Medecine Sciences : M/S|March 21, 2025
[Nobel Prize in physics 2024 : John J. Hopfield and Geoffrey E. Hinton. From Hopfield and Hinton to AlphaFold: The 2024 Nobel Prize honors the pioneers of deep learning]Alaedine Benani, Emmanuel Messas
Presse Medicale (Paris, France : 1983)|August 15, 2017
Tristan Mirault, Henri Guillet, Emmanuel Messas
The New England Journal of Medicine|July 6, 2007
Intermittent claudicationJoseph Emmerich, Emmanuel Messas, Jean-Noel Fiessinger
Lancet (London, England)|August 17, 2024
Limitations of non-invasive ultrasound therapy for valve stenosis - Authors' replyEmmanuel Messas, Alexander Ijsselmuiden, Danijela Trifunović-Zamaklar
Circulation|February 18, 2010
Letter by Messas et al regarding article, "Initial results of posterior leaflet extension for severe type IIIb ischemic mitral regurgitation"Emmanuel Messas, Albert A Hagège, Joseph Emmerich
European Journal of Haematology|May 7, 2014
Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcomeTristan Mirault, Delphine Rea, Arshid Azarine, et al.
Presse Medicale (Paris, France : 1983)|May 3, 2008
[Treatment perspectives for critical limb ischemia: gene and cell therapy]Elisa Pasqualoni, Emmanuel Messas, Jean-Noël Fiessinger, et al.
Bulletin Du Cancer|June 20, 2022
[French Chronic Myeloid Leukemia Intergroup 2022 recommendations for managing the risk of cardiovascular events on ponatinib in chronic myeloid leukemia]Delphine Réa, Emmanuel Messas, Tristan Mirault, et al.
Pageof 14

Showing results (1-10 of 134) with videos related to

Sort By:
Pageof 14
Archives of Cardiovascular Diseases|June 2, 2024
Non-invasive ultrasound therapy for aortic valve stenosis: State of the artEmmanuel Messas
Archives of Cardiovascular Diseases|May 28, 2013
Ischemic mitral regurgitation: new conceptsCatherine Szymanski, Emmanuel Messas
Medecine Sciences : M/S|March 21, 2025
[Nobel Prize in physics 2024 : John J. Hopfield and Geoffrey E. Hinton. From Hopfield and Hinton to AlphaFold: The 2024 Nobel Prize honors the pioneers of deep learning]Alaedine Benani, Emmanuel Messas
Presse Medicale (Paris, France : 1983)|August 15, 2017
Tristan Mirault, Henri Guillet, Emmanuel Messas
The New England Journal of Medicine|July 6, 2007
Intermittent claudicationJoseph Emmerich, Emmanuel Messas, Jean-Noel Fiessinger
Lancet (London, England)|August 17, 2024
Limitations of non-invasive ultrasound therapy for valve stenosis - Authors' replyEmmanuel Messas, Alexander Ijsselmuiden, Danijela Trifunović-Zamaklar
Circulation|February 18, 2010
Letter by Messas et al regarding article, "Initial results of posterior leaflet extension for severe type IIIb ischemic mitral regurgitation"Emmanuel Messas, Albert A Hagège, Joseph Emmerich
European Journal of Haematology|May 7, 2014
Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcomeTristan Mirault, Delphine Rea, Arshid Azarine, et al.
Presse Medicale (Paris, France : 1983)|May 3, 2008
[Treatment perspectives for critical limb ischemia: gene and cell therapy]Elisa Pasqualoni, Emmanuel Messas, Jean-Noël Fiessinger, et al.
Bulletin Du Cancer|June 20, 2022
[French Chronic Myeloid Leukemia Intergroup 2022 recommendations for managing the risk of cardiovascular events on ponatinib in chronic myeloid leukemia]Delphine Réa, Emmanuel Messas, Tristan Mirault, et al.
Pageof 14